Mutation in the gene coding for coagulation factor v and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men

New England Journal of Medicine

Volumn 332, Issue 14, 1995, Pages 912-917

  Ridker, Paul M ^a   Hennekens, Charles H ^a   Lindpaintner, Klaus ^a   Stampfer, Meir J ^a   Eisenberg, Paul R ^a   Miletich, Joseph P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ADENINE; BLOOD CLOTTING FACTOR 5; GUANINE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; POINT MUTATION; PRIORITY JOURNAL; STROKE;

AGED; BASE SEQUENCE; CEREBROVASCULAR DISORDERS; CONFIDENCE INTERVALS; FACTOR V; FOLLOW-UP STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMAN; MALE; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; POINT MUTATION; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOPHLEBITIS;

EID: 0028910906     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199504063321403     Document Type: Article

References (29)

1. Dahlback B, Hildebrand B Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994; 91.: 1396-1400
2. Bertina RM, Koeleman BPC, Koster T, Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369.: 64-67
3. Voorberg J, Roelse J, Koopman R, Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343.: 1535-1536
4. Zoller B, Dahlback B Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343.: 1536-1538
5. Dahlback B, Carlsson M, Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C.: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90.: 1004-1008
6. Svensson PJ, Dahlback B Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330.: 517-522
7. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM Venous thrombosis due to poor anticoagulant response to activated protein C.: Leiden Thrombophilia Study. Lancet 1993; 342.: 1503-1506
8. Griffin JH, Evatt B, Wideman C, Fernandez JA Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82.: 1989-1993
9. Halbmayer WM, Haushofer A, Schon R, Fischer M The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5.: 51-57
10. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG Inherited predisposition to thrombosis. Cell 1993; 72.: 477-480
11. Heijboer H, Brandjes DPM, Buller HR, Sturk A, ten Cate JW Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323.: 1512-1516
12. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311.: 501-505
13. Meade TW, Mellows S, Brozovic M, Haemostatic function and ischaemic heart disease.: principal results of the Northwick Park Heart Study. Lancet 1986; 2.: 533-537
14. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB Fibrinogen and risk of cardiovascular disease.: the Framingham Study. JAMA 1987; 258.: 1183-1186
15. Fowkes FGR, Lowe GDO, Housley E, Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342.: 84-86
16. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90.: 2236-2240
17. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341.: 1165-1168
18. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343.: 940-943
19. Hamsten A, Wiman B, de Faire U, Blomback M Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313.: 1557-1563
20. Hamsten A, de Faire U, Walldius G, Plasminogen activator inhibitor in plasma.: risk factor for recurrent myocardial infarction. Lancet 1987; 2.: 3-9
21. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321.: 129-135
22. World Health Organization. Ischemic heart disease registers.: report of the Fifth work Group, including a second revision of the operating protocol, Copenhagen, Denmark, April 26-29, 1971. Copenhagen, Denmark.: World Health Organization, Regional Office for Europe, 1971.
23. Hennekens CH, Buring JE. Epidemiology in medicine. Boston.: Little, Brown, 1987.
24. Anderson FA Jr, Wheeler HB, Goldberg RJ, A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism.: the Worcester DVT Study. Arch Intern Med 1991; 151.: 933-938
25. Hirsh J, Genton E, Hull R. Venous thromboembolism. New York.: Grune & Stratton, 1981.
26. Dalen JE, Alpert JS Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17.: 257-270
27. Goldhaber SZ, ed. Pulmonary embolism and deep venous thrombosis. Philadelphia.: W.B. Saunders, 1985.
28. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154.: 861-866
29. Prandoni P, lensing AWA, Buller HR, Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327.: 1128-1133